Pharvaris (PHVS) Competitors $16.53 -0.19 (-1.14%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$16.52 -0.01 (-0.03%) As of 05/30/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. ALVO, VKTX, CPRX, MTSR, MOR, SRRK, PTGX, CRNX, MLTX, and IMVTShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Alvotech (ALVO), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Metsera (MTSR), MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), MoonLake Immunotherapeutics (MLTX), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Alvotech Viking Therapeutics Catalyst Pharmaceuticals Metsera MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals MoonLake Immunotherapeutics Immunovant Pharvaris (NASDAQ:PHVS) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings. Is PHVS or ALVO more profitable? Pharvaris has a net margin of 0.00% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -38.52% -36.69% Alvotech -123.47%N/A -35.87% Does the MarketBeat Community prefer PHVS or ALVO? Pharvaris received 31 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 66.67% of users gave Pharvaris an outperform vote while only 50.00% of users gave Alvotech an outperform vote. CompanyUnderperformOutperformPharvarisOutperform Votes3866.67% Underperform Votes1933.33% AlvotechOutperform Votes750.00% Underperform Votes750.00% Which has better earnings and valuation, PHVS or ALVO? Pharvaris has higher earnings, but lower revenue than Alvotech. Pharvaris is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$109.18M-$3.01-5.49Alvotech$585.60M5.96-$551.73M$0.3731.30 Does the media prefer PHVS or ALVO? In the previous week, Alvotech had 7 more articles in the media than Pharvaris. MarketBeat recorded 11 mentions for Alvotech and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.55 beat Alvotech's score of 0.71 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alvotech 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate PHVS or ALVO? Pharvaris presently has a consensus price target of $40.67, indicating a potential upside of 146.02%. Alvotech has a consensus price target of $18.00, indicating a potential upside of 55.44%. Given Pharvaris' higher probable upside, equities analysts plainly believe Pharvaris is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Alvotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, PHVS or ALVO? Pharvaris has a beta of -2.85, indicating that its share price is 385% less volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. SummaryPharvaris beats Alvotech on 8 of the 14 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$874.29M$6.58B$5.41B$8.40BDividend YieldN/A2.64%5.28%4.17%P/E Ratio-5.908.6926.9519.78Price / SalesN/A237.77405.52134.13Price / CashN/A65.8538.2534.64Price / Book2.086.336.744.50Net Income-$109.18M$143.99M$3.23B$248.20M7 Day Performance3.38%1.06%1.24%1.00%1 Month Performance-10.55%-0.17%6.15%8.02%1 Year Performance-12.82%-2.58%25.23%8.86% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris2.1402 of 5 stars$16.53-1.1%$40.67+146.0%-12.5%$874.29MN/A-5.9030Positive NewsHigh Trading VolumeALVOAlvotech2.4006 of 5 stars$10.28+3.4%$18.00+75.1%-15.9%$3.10B$585.60M-5.564Short Interest ↓VKTXViking Therapeutics4.5863 of 5 stars$26.98-2.7%$87.15+223.0%-56.3%$3.03BN/A-26.9820Positive NewsGap DownCPRXCatalyst Pharmaceuticals4.8813 of 5 stars$24.49+1.6%$32.29+31.8%+54.5%$2.99B$534.65M20.7580Positive NewsAnalyst RevisionMTSRMetseraN/A$27.30-2.7%$47.00+72.2%N/A$2.87BN/A0.0081News CoverageGap DownMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.2666 of 5 stars$30.00-1.5%$42.67+42.2%+210.2%$2.85B$33.19M-12.77140Trending NewsInsider TradePTGXProtagonist Therapeutics3.9476 of 5 stars$45.66-0.5%$65.44+43.3%+70.6%$2.83B$207.80M17.17120News CoveragePositive NewsAnalyst DowngradeShort Interest ↓CRNXCrinetics Pharmaceuticals3.6686 of 5 stars$29.76-1.2%$74.56+150.5%-32.6%$2.79B$760,000.00-7.98210Positive NewsMLTXMoonLake Immunotherapeutics2.1573 of 5 stars$38.93+1.1%$78.71+102.2%-4.8%$2.49BN/A-30.182Positive NewsAnalyst RevisionGap UpIMVTImmunovant2.2501 of 5 stars$14.46-0.7%$38.33+165.1%-43.7%$2.46BN/A-5.52120News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst RevisionGap Down Related Companies and Tools Related Companies Alvotech Alternatives Viking Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Metsera Alternatives MorphoSys Alternatives Scholar Rock Alternatives Protagonist Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Immunovant Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHVS Stock Free PHVS Stock Alerts